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excluded from the study. Statistical analysis was carried out with
SPSS 14.0 for Windows. We created Kaplan-Meier survival
curves (at 2170 days) and calculated chi-square values (Mantel-
Cox log rank test). RESULTS: Altogether N = 3346 consecutive
patients from the whole country were included into the study
(mean age = 77.90 ± 8.458). A total of 2558 patients (mean age
= 78.14 ± 8.410) had displaced while 788 patients (mean age =
77.14 ± 8.571) had non-displaced medial femoral neck fracture.
One-way analysis of variance (ANOVA) showed signiﬁcant dif-
ference in the mean age of the two groups of patients (F = 8.412,
P = 0.004). Overall survival at 5 years follow up was 33.97 %
for patients with displaced and 42.26 % for patients with non-
displaced medial femoral neck fracture. Statistical analysis
showed that type of fracture had a highly signiﬁcant effect on
mortality (log rank test 18.17, df = 1, p < 0.001). CONCLU-
SION: We found signiﬁcant difference in survival of patients
depending on the type of medial femoral neck fracture (displaced
or non-displaced). Although survival is inﬂuenced by signiﬁcant
difference in the mean age of the two groups of patients, the type
of fracture is important regarding survival.
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OBJECTIVES: Chronic low-back pain related to osteoarthritic
changes of the lumbar spine has a signiﬁcant economic impact
on health care budgets worldwide. Anterior-Lumbar-Interbody-
Fusion (ALIF) surgery can be an effective treatment option after
non-operative therapy fails. Frequently, the affected vertebrae are
fused together using bone (autograft) from patient’s hip, which
requires additional surgery and leads to increased co-morbidity,
blood loss, infection rate, and pelvic instability. We assessed 
the cost-effectiveness of rhBMP-2 compared with autograft in
spine fusion surgery over two years from both a health care
payer’s and societal perspectives in Sweden and Denmark.
METHODS: An economic model was developed to evaluate 
differences in the two-year results between spine-fusion surgery
with rhBMP-2 and fusion with bone autograft. The cost and
health-related quality-of-life associated with both arms were 
estimated for two years after surgery. Data were obtained 
from a previously published analysis of pooled data, in which
patients in the rhBMP-2 arm showed signiﬁcant clinical impro-
vements after surgery compared to standard therapy. Costs 
were obtained from NordDRG and DkDRG and are reported 
in 2005 values. RESULTS: In Sweden, from the health care
payer’s perspective, using rhBMP-2 (€2800) lead to an incre-
mental cost-effectiveness ratio (ICER) of €7311/QALY, whereas
in Denmark, using rhBMP-2 (€3100) lead to an ICER of
€10,475/QALY. Signiﬁcant reduction in secondary interventions,
and better fusion rates associated with rhBMP-2 treatment
resulted in faster return to work and reduced productivity loss.
Therefore, rhBMP-2 was a dominant treatment option from soci-
etal perspective in both countries. These savings offset the
upfront cost of rhBMP-2 therapy. CONCLUSION: The standard
use of rhBMP-2 in ALIF surgery is a cost-effective treatment
option in Sweden and Denmark from the payer’s perspective and
a cost-saving option from the societal perspective, both in
Sweden and in Denmark.
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OBJECTIVES: To generate national estimates of inpatient costs,
length of stay (LOS), and probability of death in US hospital-
izations for blunt or penetrating trauma, stratiﬁed by injury
severity and trauma center designation of the admitting facility.
METHODS: Discharge data from the 2002 HCUP Nationwide
Inpatient Sample were analyzed for 596,762 hospitalizations
(unweighted n = 122,706) for blunt or penetrating trauma. An
injury severity score (ISS) was calculated for each admission
using the ICDMAP90 software package; mutually exclusive cat-
egories corresponding to increasing injury severity were identi-
ﬁed. Data on admitting facilities’ trauma center designation were
obtained from the American Hospital Association. Stays for
patients either admitted from, or transferred to, another inpa-
tient facility were excluded. Weighted estimates of costs, LOS,
and probability of death were calculated for each stay.
RESULTS: Most admissions (64.3%) were for low severity
injuries (ISS = 0–9); critical injuries (ISS = 25+) represented 6.4%
of admissions. More than half (54.5%) of all admissions were
to non-trauma centers; Level I, II, and III/IV trauma centers rep-
resented 20.5%, 20.2%, and 4.1% of admissions, respectively.
Overall, inpatient costs increased substantially with injury sever-
ity, ranging from $8806 for low severity admissions to $40,255
for critical admissions. LOS and probability of death also
increased from low to critical injury severity (5.2 to 13.2 days,
2.4% to 28.3%, respectively). Costs, LOS, and probability of
death decreased from Level I to III/IV trauma centers ($18,696
to $5924, 7.0 to 4.7 days, 5.7% to 3.2%, respectively); for non-
trauma centers, these outcomes were $11,411, 6.4 days, and
4.4%, respectively. CONCLUSION: This is one of the ﬁrst
studies to quantify differences in inpatient costs and outcomes
for traumatic injury across varying levels of injury severity and
trauma center designation, in a multi-payer US population. Sub-
stantial variation within these characteristics was observed for
all outcomes evaluated. Providers, payers, and other decision
makers should be aware of these differences.
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